ClinicalTrials.gg
TerminatedNCT04294459Updated Sep 17, 2025Results posted

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

A Phase 1/2 interventional study of Isatuximab SAR650984 and Acetaminophen (paracetamol) or equivalent in Immune System Disorder, sponsored by Sanofi. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Terminated due to non-safety reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Primary Objectives:

  • Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates.
  • Phase 2: To evaluate the efficacy of isatuximab in desensitization of participants awaiting kidney transplantation.

Secondary Objectives:

  • Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates.
  • To characterize the pharmacokinetic (PK) profile of isatuximab in kidney transplant candidates.
  • To evaluate the immunogenicity of isatuximab.
  • To assess the overall efficacy of isatuximab in desensitization of participants awaiting kidney transplantation.
Read the detailed description

The study had a screening period of up to 28 days, a treatment period of up to 12 weeks, a site visit FUP of up to 26 weeks, and an extended follow-up (FUP) until study cut-off.

The study duration involved site visit per participant (i.e., screening, treatment, site visit FUP was approximately 42 weeks.

The study duration included extended FUP per participant was approximately 97.7 weeks (depending on when the participant was enrolled).

02

Conditions studied

  • Immune System Disorder

Keywords

  • Anti-CD38 monoclonal antibody
03

In context

Immune System Diseases

428 studies on the registry are indexed under Immune System Diseases; 86 are open to participants now.

This study's enrollment of 23 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.

Browse Immune System Diseases studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic kidney disease (CKD) and active candidate on the kidney donor waitlist at the time of screening.
  • (BMI) \</=40 kg/m\^2.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed .

For Participants in Cohort A: active candidates on the kidney waitlist with living donor.

For Participants in Cohort B: active candidates on the kidney waitlist with no living donor cleared for donation.

Exclusion criteria

Exclusion criteria:

  • Significant cardiac dysfunction.
  • Known active, recurrent, or chronic infection.
  • Active lupus or uncontrolled diabetes.
  • Prior treatment with rituximab within 6 months from SAR650984 administration.
  • Inadequate organ and bone marrow function at screening.
  • Pregnant or breastfeeding women or women who intend to become pregnant during participation in the study.
  • Known intolerance or to any component of SAR650984 or pre-medications.
  • Participants who were not suitable for participation as judged by the Investigator.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort A: Participants with cPRA >=99.90%

    Participants with calculated panel reactive antibodies (cPRA) \>=99.90% (indicating active candidates on kidney transplant waitlist) received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, once weekly (QW) for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then every 2 weeks (Q2W) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events (AEs) or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).

    Drug: Isatuximab SAR650984 · Drug: Acetaminophen (paracetamol) or equivalent · Drug: Ranitidine or equivalent · Drug: Diphenhydramine or equivalent · Drug: Methylprednisolone or equivalent · Drug: Montelukast or equivalent

  • Experimental
    Cohort B: Participants with cPRA 80.00% to 99.89%

    Participants with cPRA between 80.00% to 99.89% (indicating active candidates on kidney transplant waitlist with no living donor cleared for donation) received isatuximab 10 mg/kg, IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then Q2W for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).

    Drug: Isatuximab SAR650984 · Drug: Acetaminophen (paracetamol) or equivalent · Drug: Ranitidine or equivalent · Drug: Diphenhydramine or equivalent · Drug: Methylprednisolone or equivalent · Drug: Montelukast or equivalent

Interventions

  • Pharmaceutical form: Solution for infusion Route of administration: Intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: Tablets Route of administration: Oral

  • DrugRanitidine or equivalent

    Pharmaceutical form: Solution Route of administration: Intravenous

  • DrugDiphenhydramine or equivalent

    Pharmaceutical form: Solution Route of administration: Intravenous

  • DrugMethylprednisolone or equivalent

    Pharmaceutical form: Solution Route of administration: Intravenous

  • DrugMontelukast or equivalent

    Pharmaceutical form: Tablets Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug until study cut-off date).

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  2. Number of Participants With Hematological Abnormalities

    Abnormal hematological parameters assessed were anemia, platelet count decreased, neutrophil count decreased, lymphocyte count decreased and monocytes. The hematological abnormality grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Monocytes were assessed as per potentially clinically significant abnormality (PCSA) criteria defined as: greater than (\>) 0.7\*10\^9/L.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  3. Number of Participants With Renal Function Abnormalities

    Abnormal renal parameters assessed were creatinine increased and estimated Glomerular Filtration Rate (eGFR). The renal function abnormality grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. eGFR was assessed as per PCSA criteria: 60 (less than equal to) \<= to less than (\<) 90 milliliter/minute/1.73 meter square (mL/min/1.73m\^2) (Mild), 30\<= to \<60 mL/min/1.73m\^2 (Moderate), 15\<=to \<30 mL/min/1.73m\^2 (Severe), \<15 mL/min/1.73m\^2 (End Stage Renal Disease).

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  4. Number of Participants With Abnormal Electrolytes Parameters

    Abnormal electrolyte parameters assessed were hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, blood bicarbonate decreased, hypermagnesemia, hypomagnesemia and chloride. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Chloride was estimated as per PCSA criteria: \<80 millimoles per liter (mmol/L) and \>115 mmol/L.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  5. Number of Participants With Abnormal Metabolism Parameters

    Abnormal metabolism parameters assessed were hypoglycemia, hypoalbuminemia and glycated Hemoglobin (HbA1c). The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. HbA1c was estimated as per PCSA criteria: \>8%.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  6. Number of Participants With Liver Function Abnormalities

    Abnormal liver function parameters assessed were Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Alkaline phosphatase (ALP) increased, and Total bilirubin (TB) increased. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  7. Percentage of Participants With Response

    Response was defined as the percentage of participants meeting at least one of the predefined desensitization efficacy criteria as measured by single antigen bead (SAB) assay as follows: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer (\>=75% reduction from Baseline) to achieve target cPRA; elimination of \>=1 human leukocyte antigen (HLA) antibody (i.e., mean fluorescence intensity \[MFI\] reduced to \<2000) as measured by a SAB assay, for antibodies with Baseline MFI \>=3000.

    Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

Secondary outcomes

  1. Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab

    Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

    Time frame: At End of infusion on Cycle 1 Day 1

  2. PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab

    Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

  3. PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab

    Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

  4. PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab

    Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification calculated using non-compartmental analysis after the first infusion of isatuximab.

    Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

  5. PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab

    Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

  6. PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab

    Ctrough was the plasma concentration of isatuximab observed just before (pre-dose) treatment administration.

    Time frame: Cycle 2 Day 1

  7. PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab

    AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using trapezoidal method after first infusion of isatuximab.

    Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

  8. Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab

    ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  9. Duration of Response (DOR)

    Duration of response (DOR) was defined as time (in weeks) from laboratory sample collection date used in determining a participant to be a responder (defined as participants meeting at least one of the predefined desensitization efficacy criteria: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer \[\>=75% reduction from Baseline\] to achieve target cPRA; elimination of \>=1 anti-HLA antibody i.e. MFI reduced to \<2000 as measured by a SAB assay, for antibodies with Baseline MFI \>=3000) up to the laboratory sample collection date when participant was confirmed as no longer meeting any response criterion (i.e., non-responder) or the date of death due to any cause, whichever occurs first. DOR was analyzed using Kaplan-Meier method.

    Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

  10. Number of Participants Achieving Target cPRA

    Target calculated panel reactive antibodies (cPRA) was defined as the reduction of cPRA required to achieve at least 100% increase of likelihood of compatible donor (LCD). Number of participants who achieved target cPRA was assessed using the Organ Procurement and Transplantation Network (OPTN) calculator during the specified timepoint were reported in this outcome measure. Participants who retained their target cPRA values were censored at the date of the last available laboratory assessment achieving their target cPRA.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  11. Duration for Achieving Target cPRA

    Duration of achieving target cPRA was defined as the time (in weeks) from laboratory sample collection date of achieving target cPRA (defined as the reduction of cPRA required to achieve at least 100% increase of LCD) the first time up to the laboratory sample collection date when no longer achieving target cPRA calculated using OPTN calculator or the date of death due to any cause, whichever occurs first. The duration of achieving target cPRA was assessed using the Kaplan-Meier method.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  12. Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction

    Number of participants with anti-HLA-antibody (Baseline MFI \>=3000) reduced to \<2000 as measured using a SAB assay per central laboratory assessment was reported in this outcome measure. Participants were categorized in various categories of number of antibodies which were reduced as: none, 1-5, \>5-10, \>10-15, and \>15. If multiple visits had the same number of total anti-HLA antibody reduction, the last visit data was summarized.

    Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

  13. Time to First Transplant Offer

    Time to first transplant offer was defined as time (in days) from date of first study treatment dose up to date of first kidney transplant offer. Data on transplant status were collected and followed up until study cut-off date.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  14. Time to Transplant

    Time to transplant was defined as time (in days) from date of first study treatment dose up to date of kidney transplant. Data on transplant status were collected and followed up until study cut-off date.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  15. Number of Kidney Transplant Offers

    Number of kidney transplants offers received for each participant was reported in the outcome measure. Data on transplant offers were collected and followed up until study cut-off date.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  16. Time to First Antibody Mediated Rejection (AMR) Episode

    Time to first AMR was defined as time from date of first study treatment dose up to date of biopsy with first AMR (defined as the graft rejection due to generation of antibodies against the graft). Transplanted participants without any AMR were censored at the participant's last assessment or contact date collected in the study or at the analysis cut-off date, whichever was earlier.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  17. Percentage of Participants Who Experienced Any Antibody Mediated Rejection (AMR)

    Antibody mediated rejection was defined as the graft rejection due to generation of antibodies against the graft. The number of participants with AMR field checked as 'yes' based on the graft rejection biopsy in the electronic case report form was considered.

    Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

  18. Number of Participants With Graft Survival at 6 Months Post-Transplant

    Number of participants with graft survival status as functioning at 6-months post-transplant was reported in this outcome measure.

    Time frame: At 6 Months post-transplant

07

Results

Posted May 30, 2023
Limitations and caveats
Sponsor decided to terminate the study for non-safety reasons on 02 May 2022. Based on available clinical data at time of interim analysis, it was determined that enrollment of the remaining participants was unlikely to have any significant impact on the study results and hence the trial was stopped. All 23 participants enrolled in the study were followed-up per protocol until the planned study termination date.

Participant flow

Study was conducted at 6 active sites in 2 countries. A total of 23 participants were enrolled between 18 Jun 2020 and 02 Nov 2021 and received isatuximab monotherapy.

Participant flow — Overall Study
MilestoneCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Started1211
Completed1210
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug until study cut-off date).

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
TEAEs34
TESAEs00
PrimaryNumber of Participants With Hematological Abnormalities

Abnormal hematological parameters assessed were anemia, platelet count decreased, neutrophil count decreased, lymphocyte count decreased and monocytes. The hematological abnormality grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Monocytes were assessed as per potentially clinically significant abnormality (PCSA) criteria defined as: greater than (\>) 0.7\*10\^9/L.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hematological Abnormalities
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Anemia: Grade 168
Anemia: Grade 232
Anemia: Grade 300
Anemia: Grade 400
Platelet count decreased: Grade 126
Platelet count decreased: Grade 200
Platelet count decreased: Grade 300
Platelet count decreased: Grade 400
Neutrophil count decreased: Grade 100
Neutrophil count decreased: Grade 200
Neutrophil count decreased: Grade 300
Neutrophil count decreased: Grade 400
Lymphocyte count decreased: Grade 142
Lymphocyte count decreased: Grade 211
Lymphocyte count decreased: Grade 310
Lymphocyte count decreased: Grade 400
Monocytes (PCSA) > 0.7*10^9/L33
PrimaryNumber of Participants With Renal Function Abnormalities

Abnormal renal parameters assessed were creatinine increased and estimated Glomerular Filtration Rate (eGFR). The renal function abnormality grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. eGFR was assessed as per PCSA criteria: 60 (less than equal to) \<= to less than (\<) 90 milliliter/minute/1.73 meter square (mL/min/1.73m\^2) (Mild), 30\<= to \<60 mL/min/1.73m\^2 (Moderate), 15\<=to \<30 mL/min/1.73m\^2 (Severe), \<15 mL/min/1.73m\^2 (End Stage Renal Disease).

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Renal Function Abnormalities
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Creatinine increased: Grade 100
Creatinine increased: Grade 200
Creatinine increased: Grade 313
Creatinine increased: Grade 4118
eGFR: 60<= - <90 mL/min/1.73m^200
eGFR: 30<= - <60 mL/min/1.73m^200
eGFR: 15<= - <30 mL/min/1.73m^200
eGFR: <15 mL/min/1.73m^21211
PrimaryNumber of Participants With Abnormal Electrolytes Parameters

Abnormal electrolyte parameters assessed were hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, blood bicarbonate decreased, hypermagnesemia, hypomagnesemia and chloride. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Chloride was estimated as per PCSA criteria: \<80 millimoles per liter (mmol/L) and \>115 mmol/L.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrolytes Parameters
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Hypernatremia: Grade 100
Hypernatremia: Grade 200
Hypernatremia: Grade 300
Hypernatremia: Grade 400
Hyponatremia: Grade 141
Hyponatremia: Grade 200
Hyponatremia: Grade 300
Hyponatremia: Grade 400
Hyperkalemia: Grade 126
Hyperkalemia: Grade 231
Hyperkalemia: Grade 312
Hyperkalemia: Grade 400
Hypokalemia: Grade 100
Hypokalemia: Grade 200
Hypokalemia: Grade 300
Hypokalemia: Grade 410
Hypercalcemia: Grade 101
Hypercalcemia: Grade 210
Hypercalcemia: Grade 300
Hypercalcemia: Grade 400
Hypocalcemia: Grade 165
Hypocalcemia: Grade 202
Hypocalcemia: Grade 300
Hypocalcemia: Grade 400
Hypermagnesemia: Grade 120
Hypermagnesemia: Grade 200
Hypermagnesemia: Grade 300
Hypermagnesemia: Grade 400
Hypomagnesemia: Grade 133
Hypomagnesemia: Grade 200
Hypomagnesemia: Grade 300
Hypomagnesemia: Grade 400
Chloride (PCSA): <80 mmol/L00
Chloride (PCSA): >115 mmol/L00
PrimaryNumber of Participants With Abnormal Metabolism Parameters

Abnormal metabolism parameters assessed were hypoglycemia, hypoalbuminemia and glycated Hemoglobin (HbA1c). The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. HbA1c was estimated as per PCSA criteria: \>8%.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Metabolism Parameters
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Hypoglycemia: Grade 112
Hypoglycemia: Grade 210
Hypoglycemia: Grade 300
Hypoglycemia: Grade 400
Hypoalbuminemia: Grade 130
Hypoalbuminemia: Grade 222
Hypoalbuminemia: Grade 300
Hypoalbuminemia: Grade 400
PrimaryNumber of Participants With Liver Function Abnormalities

Abnormal liver function parameters assessed were Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Alkaline phosphatase (ALP) increased, and Total bilirubin (TB) increased. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Liver Function Abnormalities
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
ALT increased: Grade 111
ALT increased: Grade 200
ALT increased: Grade 300
ALT increased: Grade 400
AST increased: Grade 110
AST increased: Grade 200
AST increased: Grade 300
AST increased: Grade 400
ALP increased: Grade 132
ALP increased: Grade 200
ALP increased: Grade 300
ALP increased: Grade 400
TB increased: Grade 100
TB increased: Grade 200
TB increased: Grade 300
TB increased: Grade 400
PrimaryPercentage of Participants With Response

Response was defined as the percentage of participants meeting at least one of the predefined desensitization efficacy criteria as measured by single antigen bead (SAB) assay as follows: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer (\>=75% reduction from Baseline) to achieve target cPRA; elimination of \>=1 human leukocyte antigen (HLA) antibody (i.e., mean fluorescence intensity \[MFI\] reduced to \<2000) as measured by a SAB assay, for antibodies with Baseline MFI \>=3000.

Time frame:
From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Response
percentage of participantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Percentage of Participants With Response83.3 (51.6 to 97.9)81.8 (48.2 to 97.7)
SecondaryPharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

Time frame:
At End of infusion on Cycle 1 Day 1
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab
micrograms per milliliter (mcg/mL)Cohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab290 ± 128270 ± 101
SecondaryPK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab

Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Reported as:
Mean · mcg/mL
PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
mcg/mLCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab295 ± 128285 ± 94.0
SecondaryPK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab

Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Reported as:
Median · hours
PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab
hoursCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab3.67 (2.00 to 6.03)3.40 (2.25 to 4.63)
SecondaryPK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab

Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification calculated using non-compartmental analysis after the first infusion of isatuximab.

Time frame:
At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Reported as:
Mean · mcg/mL
PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
mcg/mLCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab104 ± 41.776.3 ± 21.3
SecondaryPK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab

Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Reported as:
Median · hours
PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab
hoursCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab166.00 (49.60 to 169.00)167.00 (78.80 to 168.00)
SecondaryPK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab

Ctrough was the plasma concentration of isatuximab observed just before (pre-dose) treatment administration.

Time frame:
Cycle 2 Day 1
Reported as:
Mean · mcg/mL
PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab
mcg/mLCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab308 ± 79.4246 ± 60.6
SecondaryPK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab

AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using trapezoidal method after first infusion of isatuximab.

Time frame:
At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Reported as:
Mean · micrograms*hours/milliliter (mcg*h/mL)
PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab
micrograms*hours/milliliter (mcg*h/mL)Cohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab29400 ± 740020000 ± 5240
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Against Isatuximab

ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Treatment-induced ADA00
Treatment boosted ADA00
SecondaryDuration of Response (DOR)

Duration of response (DOR) was defined as time (in weeks) from laboratory sample collection date used in determining a participant to be a responder (defined as participants meeting at least one of the predefined desensitization efficacy criteria: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer \[\>=75% reduction from Baseline\] to achieve target cPRA; elimination of \>=1 anti-HLA antibody i.e. MFI reduced to \<2000 as measured by a SAB assay, for antibodies with Baseline MFI \>=3000) up to the laboratory sample collection date when participant was confirmed as no longer meeting any response criterion (i.e., non-responder) or the date of death due to any cause, whichever occurs first. DOR was analyzed using Kaplan-Meier method.

Time frame:
From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Reported as:
Median · weeks
Duration of Response (DOR)
weeksCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Duration of Response (DOR)NA (4.857 to NA)NA (4.143 to NA)
SecondaryNumber of Participants Achieving Target cPRA

Target calculated panel reactive antibodies (cPRA) was defined as the reduction of cPRA required to achieve at least 100% increase of likelihood of compatible donor (LCD). Number of participants who achieved target cPRA was assessed using the Organ Procurement and Transplantation Network (OPTN) calculator during the specified timepoint were reported in this outcome measure. Participants who retained their target cPRA values were censored at the date of the last available laboratory assessment achieving their target cPRA.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants Achieving Target cPRA
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Number of Participants Achieving Target cPRA42
SecondaryDuration for Achieving Target cPRA

Duration of achieving target cPRA was defined as the time (in weeks) from laboratory sample collection date of achieving target cPRA (defined as the reduction of cPRA required to achieve at least 100% increase of LCD) the first time up to the laboratory sample collection date when no longer achieving target cPRA calculated using OPTN calculator or the date of death due to any cause, whichever occurs first. The duration of achieving target cPRA was assessed using the Kaplan-Meier method.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Median · weeks
Duration for Achieving Target cPRA
weeksCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Duration for Achieving Target cPRANA (3.429 to NA)7.29 (NA to NA)
SecondaryNumber of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction

Number of participants with anti-HLA-antibody (Baseline MFI \>=3000) reduced to \<2000 as measured using a SAB assay per central laboratory assessment was reported in this outcome measure. Participants were categorized in various categories of number of antibodies which were reduced as: none, 1-5, \>5-10, \>10-15, and \>15. If multiple visits had the same number of total anti-HLA antibody reduction, the last visit data was summarized.

Time frame:
From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
None22
1-5 antibodies44
>5-10 antibodies44
>10-15 antibodies10
>15 antibodies11
SecondaryTime to First Transplant Offer

Time to first transplant offer was defined as time (in days) from date of first study treatment dose up to date of first kidney transplant offer. Data on transplant status were collected and followed up until study cut-off date.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Median · days
Time to First Transplant Offer
daysCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Time to First Transplant Offer373 (248 to 517)156 (117 to 402)
SecondaryTime to Transplant

Time to transplant was defined as time (in days) from date of first study treatment dose up to date of kidney transplant. Data on transplant status were collected and followed up until study cut-off date.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Median · days
Time to Transplant
daysCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Time to Transplant445 (373 to 517)259.5 (117 to 402)
SecondaryNumber of Kidney Transplant Offers

Number of kidney transplants offers received for each participant was reported in the outcome measure. Data on transplant offers were collected and followed up until study cut-off date.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Reported as:
Number · transplant offers
Number of Kidney Transplant Offers
transplant offersCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Number of Kidney Transplant Offers33
SecondaryTime to First Antibody Mediated Rejection (AMR) Episode

Time to first AMR was defined as time from date of first study treatment dose up to date of biopsy with first AMR (defined as the graft rejection due to generation of antibodies against the graft). Transplanted participants without any AMR were censored at the participant's last assessment or contact date collected in the study or at the analysis cut-off date, whichever was earlier.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Experienced Any Antibody Mediated Rejection (AMR)

Antibody mediated rejection was defined as the graft rejection due to generation of antibodies against the graft. The number of participants with AMR field checked as 'yes' based on the graft rejection biopsy in the electronic case report form was considered.

Time frame:
From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Graft Survival at 6 Months Post-Transplant

Number of participants with graft survival status as functioning at 6-months post-transplant was reported in this outcome measure.

Time frame:
At 6 Months post-transplant
Reported as:
Count of participants · Participants
Number of Participants With Graft Survival at 6 Months Post-Transplant
ParticipantsCohort A: Participants With cPRA >=99.90%Cohort B: Participants With Calculated Panel Reactive Antibodies (cPRA) 80.00% to 99.89%
Number of Participants With Graft Survival at 6 Months Post-Transplant10

Adverse events

Collected over From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Participants With cPRA >=99.90%1/12 (8.3%)0/12 (0%)3/12 (25%)
Cohort B: Participants With cPRA 80.00% to 99.89%0/11 (0%)0/11 (0%)4/11 (36.4%)
Most frequent other events
Most frequent other events
EventCohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%
Infusion Related ReactionInjury, poisoning and procedural complications2/123/11
Covid-19Infections and infestations0/121/11
NasopharyngitisInfections and infestations1/120/11
HeadacheNervous system disorders1/120/11
TachycardiaCardiac disorders1/120/11
Nasal CongestionRespiratory, thoracic and mediastinal disorders1/120/11
NauseaGastrointestinal disorders1/120/11
MyalgiaMusculoskeletal and connective tissue disorders1/120/11
Temporomandibular Joint SyndromeMusculoskeletal and connective tissue disorders1/120/11
ChillsGeneral disorders1/120/11

Baseline characteristics

Analysis was performed on all enrolled participants.

Age, Continuous
Age, Continuous(years)Cohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%Total
Mean49.7 ± 11.948.2 ± 12.349.0 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%Total
Female628
Male6915
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Participants With cPRA >=99.90%Cohort B: Participants With cPRA 80.00% to 99.89%Total
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American314
White4913
More than one race000
Unknown or Not Reported314
08

Study locations

6 sites
  • Investigational Site Number :8400003
    San Francisco, California 94143, United States
  • Investigational Site Number :8400001
    Rochester, Minnesota 55905, United States
  • Investigational Site Number :8400002
    New York, New York 10016, United States
  • Investigational Site Number :8400004
    Houston, Texas 77030, United States
  • Investigational Site Number :7240002
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number :7240001
    L'Hospitalet de Llobregat, Catalunya [Cataluña] 08907, Spain
09

References and documents

Publications

  • Mannon RB, Vincenti FG. Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation. J Am Soc Nephrol. 2024 Nov 1;35(11):1603-1606. doi: 10.1681/ASN.0000000000000475. Epub 2024 Aug 5. No abstract available. PubMed 39102302 ↗
  • Vincenti F, Bestard O, Brar A, Cruzado JM, Seron D, Gaber AO, Ali N, Tambur AR, Lee H, Abbadessa G, Paul JA, Dudek M, Siegel RJ, Torija A, Semiond D, Lepine L, Ternes N, Montgomery RA, Stegall M. Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant. J Am Soc Nephrol. 2024 Mar 1;35(3):347-360. doi: 10.1681/ASN.0000000000000287. Epub 2023 Dec 26. PubMed 38147137 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in May 2022, 22 months.

Results were first posted in May 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Mar 4, 2020
StartActual
Jun 18, 2020
Primary completionActual
May 2, 2022
CompletionActual
May 2, 2022
Results first posted
May 30, 2023
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04294459
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Jun 18, 2020
Primary completion
May 2, 2022
Completion
May 2, 2022
Results posted
May 30, 2023
Last update
Sep 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion